附属盈喜石药集团(01093.HK)弹近8%惟盈警金斯瑞(01548.HK)逆同业续吐4.6%
石药集团(01093.HK)公布，於深圳创业板上市附属石药新诺威(300765.SZ)预计今年上半年净利润介乎1.23-1.43亿人民币，按年增长12%-30%，主因是生产经营持续稳定发展及销售收入稳定增长所致。石药今早逆市高开逾3%重越10天及50天线後，升幅扩大，最高见13.66元(刚为百天线)，半日收13.56元，回升7.8%，为最强蓝筹，半日成交增至4,508万股，涉资5.95亿元。同为蓝筹中生(01177.HK)承过去两天吐势，今早略低开最多续跌2.5%低见8.31元，接近20天线(8.18元)获承接，掉头重越10天线(8.6元)，最高见8.98元，半日收8.91元，倒升4.6%，半日成交增至5,969万股，涉资5.17亿元。
其余医药股今早也普遍跑赢大市造好，其中复星医药(02196.HK)重越10天及100天线(24.04元及25.72元)，最高见25元，现造24.8元，反覆回升4%。绿叶制药(02186.HK)重越20天及10天线(5.78元)，最高见5.84元，现造5.8元，回升3%；石四药(02005.HK)反覆回升3.2%报7.03元，股价重越250天线(6.96元)；丽珠医药(01513.HK)反覆回升3%报19.32元，股价重越10天线(18.96元)。威高股份(1066.HK)反覆回升2.7%报7.49元。
不过，发盈警料中绩「见红」金斯瑞生物科技(01548.HK)承上周五回吐失守10天及20天线势，今早进一步失守50天线(18.48元)，最多跌7.2%低见17.66元，半日收18.14元，续吐4.6%，成交增至583万股，涉资逾1.04亿元。金斯瑞发盈警指，由於推进药物开发、生产与商业化而在美国和中国开始临床试验所产生研发费用大幅提高及进一步加强自有综合性细胞治疗平台上研发投入显着增加等因素，预计今年上半年亏损2,940-4,420万美元，扭转去年同期赚约1,760万美元。
内地带动经济增长「三头马车」数据均显胜市场预期，恒指扭转早段曾吐400点或1.4%低见28,071接守稳50天线，跟随沪深股市(扭转早段曾吐1.5%-1.6%，半日高收倒升0.8%及1.4%)掉头倒升61点或0.2%，半日收28,532。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
